Efficacy and Safety of Endoscopic Nasopharyngectomy Combined With Low-Dose Radiotherapy for Primary T1-2 Nasopharyngeal Carcinoma.


Journal

Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941

Informations de publication

Date de publication:
Historique:
entrez: 26 4 2021
pubmed: 27 4 2021
medline: 20 11 2021
Statut: ppublish

Résumé

Intensity-modulated radiotherapy (IMRT) is a widely accepted therapy for nasopharyngeal carcinoma (NPC), but it inevitably brings out radiation-related complications and seriously affects the quality of life (QoL). Endoscopic nasopharyngectomy (ENPG) has been successfully conducted in locally recurred NPC, but few studies evaluated its application in early NPC. This study aims to assess the feasibility and safety of ENPG combined with low-dose radiotherapy (LDRT) in T1-2 NPC. We recruited 37 newly diagnosed localized T1-2 NPC patients who voluntarily accepted ENPG +LDRT from June 2013 to September 2016. Meanwhile, the data of 132 T1-2 NPC patients treated with IMRT were collected and used as control group. The survival outcomes, QoL score and late RT-related sequelaes were compared between the 2 groups. After a median follow-up of 54 months, only 1 patient in ENPG+LDRT group died along with hepatic metastases. The 5-year overall survival, distant metastasis-free survival, local relapse-free survival and regional relapse-free survival in ENPG+LDRT group were 97.3%, 97.3%, 100% and 100%, which were not statistically different from the control group (97.7%, 90.2%, 95. 5%, 97.0%, respectively, all ENPG+LDRT provided satisfactory survival outcomes, and improved the QoL and reduced the incidence of sequelae for T1-2 NPC patients.

Identifiants

pubmed: 33896244
doi: 10.1177/15330338211011975
pmc: PMC8085368
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15330338211011975

Références

Cancer Commun (Lond). 2020 Mar;40(2-3):119-121
pubmed: 32189471
Curr Treat Options Oncol. 2013 Dec;14(4):475-91
pubmed: 24243165
Cancer Sci. 2020 Feb;111(2):592-600
pubmed: 31834989
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):672-682
pubmed: 32272183
Radiother Oncol. 2012 Sep;104(3):286-93
pubmed: 22995588
Eur J Cancer. 2010 Jul;46(11):1967-78
pubmed: 20451372
Head Neck. 2020 Apr;42(4):807-812
pubmed: 31976616
Expert Rev Anticancer Ther. 2015 Jan;15(1):109-19
pubmed: 25231774
Laryngoscope. 2009 Mar;119(3):516-22
pubmed: 19235750
Cancer Commun (Lond). 2019 Nov 15;39(1):75
pubmed: 31730020
Ann Oncol. 2019 Jun 1;30(6):977-982
pubmed: 30912815
Int Forum Allergy Rhinol. 2020 Aug;10(8):1001-1011
pubmed: 32452124
World J Surg Oncol. 2018 Jul 4;16(1):126
pubmed: 29973209
Lancet Oncol. 2018 Apr;19(4):461-473
pubmed: 29501366
Lancet. 2016 Mar 5;387(10022):1012-1024
pubmed: 26321262
Cancer Commun (Lond). 2019 Apr 29;39(1):22
pubmed: 31030667
Radiother Oncol. 2019 Sep;138:93-98
pubmed: 31252300

Auteurs

Benjian Zhang (B)

Department of Otolaryngology-Head and Neck Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Yiliang Li (Y)

Department of Otolaryngology-Head and Neck Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Jingjin Weng (J)

Department of Otolaryngology-Head and Neck Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Bo Huang (B)

Department of Otolaryngology-Head and Neck Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Molu Ban (M)

Department of Otolaryngology-Head and Neck Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Guiping Lan (G)

Department of Otolaryngology-Head and Neck Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Yu Lu (Y)

Department of Otolaryngology-Head and Neck Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Jianhui Luo (J)

Department of Otolaryngology-Head and Neck Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Shenhong Qu (S)

Department of Otolaryngology-Head and Neck Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Yongfeng Si (Y)

Department of Otolaryngology-Head and Neck Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH